BioNexus Gene Lab (BGLC) Shares Outstanding (Weighted Average) (2018 - 2026)

BioNexus Gene Lab's Shares Outstanding (Weighted Average) history runs 9 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 34.54% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 34.54% YoY), while the FY2025 annual figure was $1.9 million, up 4.2% from the prior year.
• Shares Outstanding (Weighted Average) came in at $2.4 million for Q1 2026 at BioNexus Gene Lab, up from $1.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $172.1 million in Q2 2022 to a low of $1.8 million in Q4 2024.
• A 5-year average of $29.3 million and a median of $14.5 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) plunged 91.59% in 2023 and surged 34.54% in 2026, its largest moves.
• BioNexus Gene Lab's Shares Outstanding (Weighted Average) stood at $14.4 million in 2022, then grew by 10.17% to $15.9 million in 2023, then slumped by 88.78% to $1.8 million in 2024, then gained by 4.2% to $1.9 million in 2025, then soared by 30.2% to $2.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $2.4 million, $1.9 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison